To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

A Multicenter, Randomized, Double-Blind, Double-Dummy , Pregaballin-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Herpetic Neuralgia

Investigate the efficacy and safety of HSK16149 capsules in Chinese herpetic Neuralgia following 4 weeks treatment in comparison to pregabalin.

Inclusion Criteria:

• Signed informed consent;
• Males or females aged 18 years and older ;
• Patients must have herpetic neuralgia;
• At Screening, pain scale (VAS) of ≥ 40 mm;
• At Screening, pain scale (NRS) of ≥ 4.

Exclusion Criteria:

• Patients have pain present for more than 1 months after the healing of the herpes zoster skin rash;
• AST/ALT > 2 × upper limit of normal (ULN), or TBIL≥1.5 × ULN;
• Serum Creatine > 176μmol/L;
• Any active infections at screening;
• History of allergic or medically significant adverse reaction to investigational products or their excipients, pregabalin or related compounds;
• Participated in another clinical study within 30 days prior to screening;
• Pregnant or breastfeeding at screening ;
• Other conditions unlikely to participate in this trial.